Solange Peters
0000-0002-0412-7143
Publication & Citation Trends
Publications
0 total
PL02.08 Perioperative vs Neoadjuvant Nivolumab for Resectable NSCLC: Patient-Level Data Analysis of CheckMate 77T vs CheckMate 816
Cited by 48
Semantic Scholar
90P Real-world (RW) post-progression outcomes and treatment (tx) patterns after first-line (1L) immuno-oncology (IO) regimens in patients (pts) with metastatic (m) NSCLC: CORRELATE OA
Cited by 1
Semantic Scholar
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes from the Phase 3 POSEIDON Trial. OA
Cited by 54
Semantic Scholar
Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic Non-Small Cell Lung Cancer and Tumor PD-L1 <1%: a Pooled Analysis.
Cited by 17
Semantic Scholar
P4.11D.09 Fianlimab-Based Combination Therapies in Patients with Advanced Non-Small Cell Lung Cancer: Trials in Progress Updates
Cited by 0
Semantic Scholar
P2.06-05 Durvalumab ± Tremelimumab + Chemotherapy in 1L Metastatic NSCLC: Characterisation of patients with PFS ≥12 months in POSEIDON OA
Cited by 0
Semantic Scholar
68P Real-world (rw) outcomes in patients (pts) with metastatic (m) NSCLC and STK11, KEAP1 and/or KRAS mutations (mut) receiving PD-(L)1-based treatment (tx): CORRELATE OA
Cited by 1
Semantic Scholar
OA17.03 Real-World Outcomes with Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutated NSCLC (PACIFIC-R) OA
Cited by 4
Semantic Scholar
Research Topics
Lung Cancer Treatments and Mutations
(399)
Cancer Immunotherapy and Biomarkers
(210)
Lung Cancer Diagnosis and Treatment
(175)
Lung Cancer Research Studies
(169)
Cancer Genomics and Diagnostics
(143)
Affiliations
Goethe University Frankfurt
Aurora Health Care
University of Bern
Università degli Studi del Piemonte Orientale “Amedeo Avogadro”
SIB Swiss Institute of Bioinformatics